The increased plasma ACE level may result in an increase in the expression levels of interleukin-6 (IL-6) and kallikrein (KLK1), which subsequently increases coronary plaque vulnerability, ulceration, and thrombosis, leading to an increased risk and mortality of cardiovascular diseases [17]. Here, IL6 is linked to cardiovascular disorder.